Re Walk Robotics Ltd. RWLK
We take great care to ensure that the data presented and summarized in this overview for ReWalk Robotics Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RWLK
Top Purchases
Top Sells
About RWLK
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.
Insider Transactions at RWLK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 02
2025
|
Jeannine Lynch VP of Market Access & Strategy |
SELL
Open market or private sale
|
Indirect |
1,591
-3.34%
|
$0
$0.64 P/Share
|
|
Aug 01
2025
|
Joseph E Turk Jr Director |
BUY
Grant, award, or other acquisition
|
Indirect |
71,839
+45.38%
|
-
|
|
Aug 01
2025
|
Hadar Levy Director |
BUY
Grant, award, or other acquisition
|
Indirect |
35,920
+41.05%
|
-
|
|
Aug 01
2025
|
Randel Richner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
35,920
+38.46%
|
-
|
|
Aug 01
2025
|
Michael Swinford Director |
BUY
Grant, award, or other acquisition
|
Indirect |
35,920
+43.87%
|
-
|
|
Aug 01
2025
|
Robert J. Marshall Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,920
+50.0%
|
-
|
|
Aug 01
2025
|
John William Sr Poduska Director |
BUY
Grant, award, or other acquisition
|
Indirect |
35,920
+39.1%
|
-
|
|
May 21
2025
|
Lawrence J Jasinski Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
1,909
-1.9%
|
$1,909
$1.26 P/Share
|
|
Jan 07
2025
|
Lind Global Fund Ii LP |
SELL
Open market or private sale
|
Indirect |
191,434
-9.13%
|
$382,868
$2.32 P/Share
|
|
Jan 06
2025
|
Lind Global Fund Ii LP |
SELL
Open market or private sale
|
Indirect |
381,676
-13.98%
|
$1,145,028
$3.24 P/Share
|
|
Dec 13
2024
|
Randel Richner Director |
SELL
Open market or private sale
|
Indirect |
4,285
-100.0%
|
$4,285
$1.68 P/Share
|
|
Dec 13
2024
|
Joseph E Turk Jr Director |
BUY
Open market or private purchase
|
Direct |
6,000
+24.47%
|
$6,000
$1.69 P/Share
|
|
Nov 25
2024
|
Michael Swinford Director |
BUY
Open market or private purchase
|
Direct |
21,622
+24.95%
|
$43,244
$2.03 P/Share
|
|
Nov 22
2024
|
Michael Swinford Director |
BUY
Open market or private purchase
|
Direct |
16,907
+28.03%
|
$16,907
$1.83 P/Share
|
|
Nov 20
2024
|
Michael Swinford Director |
BUY
Open market or private purchase
|
Direct |
16,471
+38.32%
|
$16,471
$1.84 P/Share
|
|
Sep 13
2024
|
Lawrence J Jasinski Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,672
-2.59%
|
$8,016
$3.26 P/Share
|
|
Sep 03
2024
|
Jeannine Lynch VP of Market Access & Strategy |
SELL
Open market or private sale
|
Indirect |
1,625
-3.3%
|
$4,875
$3.3 P/Share
|
|
Aug 02
2024
|
Jeannine Lynch VP of Market Access & Strategy |
SELL
Open market or private sale
|
Indirect |
1,783
-3.49%
|
$5,349
$3.84 P/Share
|
|
Aug 02
2024
|
Lawrence J Jasinski Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,665
-2.51%
|
$7,995
$3.84 P/Share
|
|
Jul 01
2024
|
Jeannine Lynch VP of Market Access & Strategy |
SELL
Open market or private sale
|
Indirect |
1,834
-3.47%
|
$5,502
$3.83 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 251K shares |
|---|---|
| Open market or private purchase | 61K shares |
| Open market or private sale | 581K shares |
|---|